Latest Regulatory News

Tartana Minerals has made significant strides in expanding its silver exploration footprint with uncontested progress on EPM 27220, covering historic high-grade silver mines. The company also restates a robust Nightflower Exploration Target and plans extensive drilling in 2026.

Element 25 Limited is making significant strides in its Butcherbird Expansion Project, targeting a manganese concentrate output of 1.1 million tonnes per annum with key contracts shortlisted and financing progressing.

Paradigm Biopharmaceuticals has published a pivotal study in PLOS ONE showing sustained pain relief and joint repair in dogs treated with pentosan polysulfate sodium, reinforcing its potential for human osteoarthritis therapy.

Revolution Private Credit Income Trust has successfully raised $60 million through a wholesale placement, strengthening its capacity to invest in senior secured loans and asset-backed securities across Australia and New Zealand.

Cyclopharm Limited has completed the initial phase of a $14 million share placement, issuing nearly 9.5 million shares at 95 cents each, with the remaining shares set for issuance later this month.

humm Group reports a $13.9 million statutory profit for 1H26, driven by commercial lending growth and strong consumer segment performance despite rising credit losses and regulatory costs.

Humm Group Limited reported a $13.9 million statutory profit for the half-year ended December 2025, despite increased credit losses and elevated costs. The company’s ongoing transformation and global expansion underpin cautious optimism for the year ahead.

humm Group Limited has posted a statutory profit after tax of $13.9 million for the half-year ended 31 December 2025, marking a 49% decline from the previous year, driven by increased credit losses and legal costs. Despite challenges, the company declared a fully franked interim dividend of 1.5 cents per share.

Racura Oncology has developed a pioneering blood test that promises to fast-track key data on its cardioprotective drug RC220, potentially shaving two years off the clinical trial timeline. This innovation also enhances patient safety and recruitment prospects in the ongoing RAC-010 CPACS trial.

Arena REIT has reported a robust HY2026 financial performance, with net operating profit rising 9% and statutory net profit surging 202%. The REIT’s active portfolio management and development pipeline underpin its confidence in sustained growth.

Arena REIT reported a remarkable 202% jump in net profit for the half-year ending December 2025, driven by significant property revaluation gains and steady rental income growth. Distributions rose 5%, supported by an expanded and fully leased portfolio of early learning and healthcare properties.

Tivan Limited’s maiden drilling at the Sandover Fluorite Project has delivered ultra high-grade fluorite assays, confirming a robust mineralised system with promising metallurgical qualities. The company is gearing up for a significant follow-up drilling campaign to expand resource definition.